Tafluprost
Generic Name: tafluprost
Brand Names:
Zioptan
11 DESCRIPTION ZIOPTAN (tafluprost ophthalmic solution) 0.0015% contains tafluprost, a fluorinated analog of prostaglandin F2α, for topical ophthalmic use. The chemical name for tafluprost is 1-methylethyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate. The molecular formula of tafluprost is C25H34F2O5 and its molecular weight is 452.53.
Overview
11 DESCRIPTION ZIOPTAN (tafluprost ophthalmic solution) 0.0015% contains tafluprost, a fluorinated analog of prostaglandin F2α, for topical ophthalmic use. The chemical name for tafluprost is 1-methylethyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate. The molecular formula of tafluprost is C25H34F2O5 and its molecular weight is 452.53.
Side Effects
6 ADVERSE REACTIONS . Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Thea Pharma Inc. at 1-833-838-4028 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Preservative-containing or nonpreserved tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration.
Warnings
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of ZIOPTAN administration in pregnant women to inform of drug-associated risks. In animal reproduction studies, intravenous administration of tafluprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal toxicities at exposures ≥5-times the human dose in rabbit and ≥2362-times the human dose in rat. (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown.
Storage
Storage: Store refrigerated at 2° to 8°C (36° to 46°F). During shipment ZIOPTAN may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. Mail-order prescriptions received after two days of the dispensing date noted in the prescribing label should not be used. Store in the original pouch.
Frequently Asked Questions
What are the side effects of Tafluprost?▼
6 ADVERSE REACTIONS . Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Thea Pharma Inc. at 1-833-838-4028 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Preservative-containing or nonpreserved tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration.
Can I take Tafluprost during pregnancy?▼
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of ZIOPTAN administration in pregnant women to inform of drug-associated risks. In animal reproduction studies, intravenous administration of tafluprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal toxicities at exposures ≥5-times the human dose in rabbit and ≥2362-times the human dose in rat. (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown.
What are the important warnings for Tafluprost?▼
4 CONTRAINDICATIONS None. None. ( 4 )
Related Medications
Aconitum Napellus - Apis Mellifera - Arnica Montana - Arsenic Trioxide - Atropa Belladonna - Calcium Fluoride - Centella Asiatica - Cinchona Officinalis Bark - Cranberry - Horse Chestnut - Iron - Lachesis Muta Venom - Mercury - Pineapple - Pulsatilla Vulgaris - Sus Scrofa Artery - Sus Scrofa Small Intestine Mucosa Lymph Follicle - Sus Scrofa Vein - Viscum Album Fruit - Witch Hazel -
aconitum napellus - apis mellifera - arnica montana - arsenic trioxide - atropa belladonna - calcium fluoride - centella asiatica - cinchona officinalis bark - cranberry - horse chestnut - iron - lachesis muta venom - mercury - pineapple - pulsatilla vulgaris - sus scrofa artery - sus scrofa small intestine mucosa lymph follicle - sus scrofa vein - viscum album fruit - witch hazel -
Standardized Insect Venom Allergenic Extract [EPC]
Temporarily relieves symptoms of venous congestion and stasis, such as: swollen legs cold feet
Queen Palm Coco Palm
queen palm coco palm
Dosage form: INJECTION, SOLUTION. Route: PERCUTANEOUS. Active ingredients: SYAGRUS ROMANZOFFIANA POLLEN (.05 g/mL). Category: BLA.
Deslanoside
deslanoside
Manufactured by NOVARTIS. Dosage form: INJECTABLE. Route: INJECTION. Active ingredients: DESLANOSIDE (0.2MG/ML). Application: NDA009282.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.